Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Declines By 31.1%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 200,100 shares, a decline of 31.1% from the December 15th total of 290,600 shares. Based on an average daily volume of 286,100 shares, the short-interest ratio is currently 0.7 days. Currently, 1.5% of the company’s shares are short sold.

Institutional Trading of NeuroSense Therapeutics

A hedge fund recently raised its stake in NeuroSense Therapeutics stock. XTX Topco Ltd lifted its position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 40.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,996 shares of the company’s stock after acquiring an additional 13,346 shares during the period. XTX Topco Ltd owned 0.34% of NeuroSense Therapeutics worth $58,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Price Performance

NRSN opened at $1.03 on Wednesday. The firm has a market capitalization of $14.08 million, a PE ratio of -1.21 and a beta of 1.30. The business’s 50-day moving average is $1.12 and its two-hundred day moving average is $1.06. NeuroSense Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.33.

NeuroSense Therapeutics (NASDAQ:NRSN) last posted its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Maxim Group reaffirmed a “hold” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 16th.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.